CoChat

Empagliflozin decreases remnant‐like particle cholesterol in type 2 diabetes patients with insulin resistance

Open access
Hattori, Sachiko · 2018 · Journal of Diabetes Investigation
Cited by 37

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aims/Introduction: Remnant lipoproteins are thought to be atherogenic. Remnant‐like particle cholesterol (RLP‐C), which reflects the levels of various kinds of remnant lipoproteins in the blood, has a significant correlation with insulin resistance. Materials and Methods: In the present study, we measured the effect of empagliflozin (EMPA) on the levels of RLP‐C, and investigated whether EMPA‐mediated change in RLP‐C is associated with a change in insulin resistance in type 2 diabetes patients who have insulin resistance. Results: Patients were allocated to receive a placebo (n = 51) or EMPA (n = 58) as an add‐on treatment. Fasting blood samples were collected before and 12 weeks after this intervention. EMPA significantly decreased glycated hemoglobin, bodyweight, systolic blood pressure, plasma triglycerides, liver transaminases and estimated glomerular filtration rate, and increased high‐density lipoprotein cholesterol. Furthermore, EMPA decreased RLP‐C and homeostatic model assessment of insulin resistance. In the placebo group, there were no significant changes in these factors except for slight increases in liver transaminases. Multiple regression analysis showed that the change in homeostatic model assessment of insulin resistance (P = 0.0102) and the change in alanine aminotransferase (P = 0.0301) were significantly associated with the change in RLP‐C in the EMPA group. The change in RLP‐C significantly correlated with the change in homeostatic model assessment of insulin resistance (Pearson correlation coefficient 0.503, 95% confidence interval 0.199–0.719; P = 0.00241). Conclusion: EMPA decreases RLP‐C levels, which is closely associated with amelioration of insulin sensitivity in diabetes patients who have insulin resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdi.12781

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Hattori, S.
Venue
Journal of Diabetes Investigation
Publisher
Wiley
Published
2017-12-27
Volume
9
Issue
4
Pages
870-874
ISSN
  • 2040-1116 (ISSN-L)
  • 2040-1124
OpenAlex
W2770289206
Cited by
37
References
5
FWCI
2.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.